GLP-1 Weight Loss

A major study published in the New England Journal of Medicine on April 30 found that semaglutide (Ozempic/Wegovy) reduced cardiovascular events by 20% in non-diabetic obese patients over a 4-year follow-up. The findings expand the case for GLP-1 drugs beyond diabetes and weight loss into heart disease prevention. Major insurers are now under pressure to broaden coverage, and Congress held hearings this week on drug pricing. The study was the largest of its kind with over 17,000 participants.